Belgium-based AARDEX Group, the world leader in medication adherence solutions, announced a strategic partnership with BIOCORP, a French company specialized in the design, development and manufacture of innovative medical devices. The alliance will further extend the comprehensive portfolio of smart solutions and connected devices available to effectively measure and manage medication adherence for patients and healthcare providers.

The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%, resulting in many life-threatening illnesses not being effectively monitored or treated. By combining BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS), the objective is to support an unbiased and precise measure of medication adherence in key therapy areas.

The first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) with AARDEX’s MEMS Adherence Software (MEMS AS), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with other BIOCORP’s connected devices, to cover further chronic conditions in the fields of injectables, respiratory and beyond.

David Dalla Vecchia, CEO and Financial Lead of AARDEX Group said: “Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP – a true pioneer in connected devices – will significantly contribute to that objective. Medication adherence is a critical issue for all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts the assessment of drug efficacy. So, this partnership will also be pivotal in enhancing the impact of academic research findings.”

Éric Dessertenne, CEO of BIOCORP, concluded, “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that precisely analyzes patient patterns and behaviours, we will go beyond just monitoring treatment adherence by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.